LAS VEGAS, Jan. 16, 2020 /PRNewswire/ -- JanOne Inc.
(NASDAQ:JAN) appoints Christopher
Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to
lead its scientific advisory board. In this role, Dr. Kevil
will chair the Company's scientific advisory board to advise on
drug development and technology strategy, assist with clinical
research, and help to advance its lead candidate TV1001SR, for the
treatment of PAD. Dr. Kevil is considered a foremost expert in the
development and analysis of various small molecules, biologics,
disease indications, pharmaceutical, medical device, and drug
delivery systems.
Most notable, is Dr. Kevil's research that led to the
development and formulation of TV1001SR, a nitrite based treatment
for PAD which has shown positive results in phase 2a trials.
Internationally recognized for his research on inflammatory
vascular pathology, specifically on and the relationship between
inflammation and vascular growth and function, he discovered
detailed mechanistic relationships between angiogenesis and
inflammation.
"We are thrilled to have Chris lead our Scientific Advisory
board, and look forward to his contributions," said Tony Isaac, CEO of JanOne. "Dr. Kevil's passion,
accomplishments and expertise in vascular inflammation, treatment
for PAD, and translational and clinical research provides an
unparalleled level of leadership that is necessary as we advance
TV1001SR into phase 2b trials."
Dr. Kevil earned his Ph.D. degree from LSU Health Shreveport in
Molecular and Cellular Physiology followed by a fellowship at the
University of Alabama at Birmingham
(UAB) with an emphasis on redox pathophysiology. Returning to LSU
Health Shreveport in the Department of Pathology, he established
cutting edge research programs regarding redox biology regulation
of peripheral vascular diseases. This led to groundbreaking
insights on how glutathione, nitrite/nitric oxide, and hydrogen
sulfide regulate vascular health during ischemia.
"The team at JanOne is committed to bringing potential
treatments for PAD and associated pain into the clinic and I look
forward to contributing my expertise to advance its clinical
candidates," said Dr. Kevil. "Their mission to treat diseases
that cause severe pain and to reduce the need for pain-relieving
prescription opioids is an important patient benefit and also
critical outcome of my research on TV1001SR."
Dr. Kevil is an Associate Editor for the American Journal of
Pathology and Editor in Chief of the Redox Biology journal, as well
as a member of numerous editorial boards including Cardiovascular
Research, American Journal of Physiology - Heart and Circulation
Physiology, Free Radical Biology and Medicine, and Frontiers in
Oxidant Physiology. He has received numerous research grant
awards and honors and has led research initiatives for the National
Institutes of Health, the American Diabetes Association, and the
American Heart Association, and other professional societies.
About JanOne
JanOne is a unique NASDAQ-listed company
offering innovative, actionable solutions that it believes can help
create an end to the opioid crisis. JanOne is dedicated to funding
resources toward innovation, technology, and education to find a
key resolution to the national opioid epidemic, which is one of the
deadliest and widespread in the country's history. The company
continues to operate its legacy businesses – ARCA Recycling and
GeoTraq – under their current brand names. JanOne's subsidiary ARCA
Recycling recycles household appliances by providing turnkey
recycling and replacement services for utilities and other sponsors
of energy efficiency programs. JanOne's subsidiary GeoTraq engages
in the development, design and, ultimately, expected sale of Mobile
IoT modules. Please visit www.janone.com for additional
information.
Media contact:
Mark Rosenberg
mark@trueparallel.com
919-412-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leading-cardiovascular-researcher-and-pad-treatment-pioneer-dr-christopher-kevil-to-chair-janone-scientific-advisory-board-300988338.html
SOURCE JanOne